Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Oxidoreductase delivery by cell therapies in cyclophosphamide-induced premature ovarian insufficiency: a mechanistic insight into ovarian rejuvenation.

Zhang YY., Chen J., Yang W., Chen Y., Zhang Y., Zhou Y.

Animal Study on Hair & Scalp, published in J Ovarian Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Ovarian Res (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41437282
PMCID
PMC12837529
DOI
10.1186/s13048-025-01912-y

Abstract (original English)

BACKGROUND: The etiologically diverse decline in ovarian function among females represents a significant contributor to the rising incidence of infertility. Recent advances in cell-based therapies, including mesenchymal stem cells (MSCs) and autologous stromal vascular fraction (SVF), has shown potential in rejuvenating ovarian function. Yet, the efficacy heterogeneity and mechanisms of action warrant further investigation for validation. METHODS: This study investigates the therapeutic efficacy of human umbilical cord-derived MSCs (HucMSCs), adipose tissue-derived MSCs (ADSCs), and stromal vascular fraction (SVF) in a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) mouse model. Equivalent doses of these cells were orthotopically administered, and their impact on ovarian function was meticulously evaluated using comprehensive functional and histological assays. RNA sequencing and proteomic analysis were employed to elucidate the underlying mechanisms. RESULTS: Our findings reveal that HucMSCs, ADSCs, and SVF robustly enhance follicle development, hormonal balance, oocyte quality, and embryonic developmental potential, leading to improved fertility outcomes. In vitro co-culture with granulosa cells (GCs) demonstrated that all three cell types significantly promoted GC proliferation. Proteomic evaluation identified oxidoreductase enzymes as key players in mit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
FemalePrimary Ovarian InsufficiencyAnimalsCyclophosphamideHumansMesenchymal Stem CellsMiceOxidoreductasesDisease Models, AnimalOvary

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research